EQT Life Sciences and the Forbion Growth Opportunities Fund led a $138m Series A funding round in VectorY.

EQT Life Sciences, a healthcare investor, and the Forbion Growth Opportunities Fund, a clinical-stage biopharmaceutical company, led a $138m Series A funding round in VectorY, a biotech company developing innovative vectorized antibody therapies for the treatment of neurodegenerative diseases, with participation from MRL Ventures Fund, Merck & Co, Rahway, Insight Partners, ALS Investment Fund and BioGeneration Ventures. “The Series A financing, supported by such a strong syndicate of European and US investors, is an endorsement of our pioneering approach, world-class team and commitment to bring much-needed therapies to patients with neurodegenerative diseases. The investment will enable us to advance our lead program VTx-002, a potentially disease-modifying therapy for ALS, into clinical development. Our program is uniquely positioned to address TDP-43 pathology, which underlies the disease in the vast majority of ALS patients. The series A will also support advancement of additional pipeline programs targeting proteinopathies in neurodegenerative diseases demonstrating the broad potential of our platform,” Sander van Deventer, VectorY CEO.